Added to YB: 2026-06-26
Pitch date: 2026-06-24
RX.V [neutral]
BioSyent Inc.
Author Info
Aurelion Research is a research analyst with a passion for markets, specializing in high‑conviction ideas across shipping, offshore drilling, and thematic equity research. Sign up for the newsletter.
Company Info
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Market Cap
CAD 160.6M
Pitch Price
N/A
Price Target
N/A
Dividend
1.57%
EV/EBITDA
12.20
P/E
17.91
EV/Sales
3.37
Sector
Pharmaceuticals
Category
growth
Biosyent Inc (CVE: RX)
RX.V (overview): Canadian specialty pharma compounder. Acquires/licenses proven foreign healthcare products. Core FeraMAX iron supplement (#1 in Canada, MSD-HSD growth). FY25 rev +23%, 21% net margin, 70% EBITDA-to-cash. CEO owns 19.5%. Recent dental/oral acquisition at 6x EBITDA growing 10-15%. Trades 8.4x 2027 EBITDA w/ double-digit earnings growth. Buybacks + capital allocation track record. Risks: CEO 66 (retirement), FeraMAX growth. Long-term opportunity, no near-term catalyst.
Read full article (3 min)